Clinical Trial

Testing Experimental Treatment for Cystic Fibrosis

Study Description

A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222

This study will evaluate the safety, tolerability, and efficacy of ABBV-3067 given alone and in combination with various doses of ABBV-2222 in adults with Cystic Fibrosis who are homozygous for the F508del mutation.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - ABBV-3067

Tablet or capsule taken orally

Drug - Placebo ABBV-3067

Tablet or capsule taken orally

Drug - ABBV-2222

Capsule taken orally

Drug - Placebo ABBV-2222

Capsule taken orally

Additional Information

Official Study Title

A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation

Clinical Trial ID

NCT03969888

ParticipAid ID

eVOjza